Stay updated on Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Sign up to get notified when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.

Latest updates to the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page
- Check2 days agoNo Change Detected
- Check9 days agoChange DetectedMajor update: page now includes a government funding status notice and indicates version 3.2.0, replacing the previous 3.1.0.SummaryDifference2%
- Check16 days agoChange DetectedCore terminology updated from 'Plasma cell myeloma' to 'Multiple myeloma' and the page version bumped to v3.1.0.SummaryDifference0.2%
- Check23 days agoNo Change Detected
- Check30 days agoChange DetectedUpdated revision from v3.0.1 to v3.0.2; removed the 'Back to Top' element.SummaryDifference0.2%
- Check37 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1.SummaryDifference0.2%
- Check45 days agoChange DetectedThe web page has been updated to include a new facility name and location, along with a list of publications related to multiple myeloma, while several previous location details and related topics have been removed.SummaryDifference6%
- Check59 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.1%
Stay in the know with updates to Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Letetresgene Autoleucel+Pembrolizumab in NY-ESO-1+ MM Clinical Trial page.